-+ 0.00%
-+ 0.00%
-+ 0.00%

Sagimet Biosciences closes USD 115 million underwritten Series A common stock, pre-funded warrant offering

PUBT·10/01/2026 20:32:02
Listen to the news
Sagimet Biosciences closes USD 115 million underwritten Series A common stock, pre-funded warrant offering
  • Sagimet Biosciences closed an underwritten offering of 8,750,010 shares of Series A common stock priced at USD 10.00.
  • Investors also bought pre-funded warrants to purchase 2,750,010 Series A common shares at USD 9.9999 each.
  • Pre-funded warrants carry a USD 0.0001 exercise price, exercisable immediately.
  • Gross proceeds totaled about USD 115 million before underwriting discounts, commissions, and offering expenses.
  • Net proceeds earmarked for Phase 3 denifanstat acne trial, pre-launch work, TVB-3567 through Phase 2 topline, other R&D, general purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610011631PRIMZONEFULLFEED9838257) on October 01, 2026, and is solely responsible for the information contained therein.